Clinical trial
A Phase 1/2, First-in-Human, Open-Label, Dose Escalation and Expansion Study of STAR0602, a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule, in Subjects With Unresectable, Locally Advanced, or Metastatic Solid Tumors That Are Antigen-rich (START-001)
NCT05592626 is registered in ClinicalTrials.gov with Marengo Therapeutics, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1/2, First-in-Human, Open-Label, Dose Escalation and Expansion Study of STAR0602, a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule, in Subjects With Unresectable, Locally Advanced, or Metastatic Solid Tumors That Are Antigen-rich (START-001)
- Lead sponsor
- Marengo Therapeutics, Inc.
- Phase
- Phase 1/2
- Overall status
- Recruiting
- Start date
- January 4, 2023
- Completion date
- September 30, 2027
- Enrollment
- 366 (estimated)
- Sites
- 19
Conditions
As the registry lists them; a condition with its own page is linked.
abdominal neoplasm, advanced solid tumors, carcinoma, colorectal cancer, epstein-barr virus infections, genital neoplasm, female, lung neoplasm, neoplasms, neoplasms by site, nsclc (non-small cell lung cancer), papillomavirus infection, urogenital neoplasms, vulvar diseases, vulvar neoplasms